Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

6VY5

Crystal structure of Nipah receptor binding protein head domain in complex with human neutralizing antibody HENV-26

Summary for 6VY5
Entry DOI10.2210/pdb6vy5/pdb
DescriptorAnti-Hendra receptor binding protein antibody HENV-26 Fab heavy chain, Anti-Hendra receptor binding protein antibody HENV-26 Fab light chain, receptor binding protein, ... (4 entities in total)
Functional Keywordshenipavirus, hendra virus, receptor binding protein, antibody, antibody-antigen complex, viral protein-immune system complex, viral protein/immune system
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains3
Total formula weight97185.03
Authors
Dong, J.,Crowe, J.E. (deposition date: 2020-02-25, release date: 2021-01-06, Last modification date: 2024-10-30)
Primary citationDong, J.,Cross, R.W.,Doyle, M.P.,Kose, N.,Mousa, J.J.,Annand, E.J.,Borisevich, V.,Agans, K.N.,Sutton, R.,Nargi, R.,Majedi, M.,Fenton, K.A.,Reichard, W.,Bombardi, R.G.,Geisbert, T.W.,Crowe Jr., J.E.
Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein.
Cell, 183:1536-1550.e17, 2020
Cited by
PubMed Abstract: Hendra (HeV) and Nipah (NiV) viruses are emerging zoonotic pathogens in the Henipavirus genus causing outbreaks of disease with very high case fatality rates. Here, we report the first naturally occurring human monoclonal antibodies (mAbs) against HeV receptor binding protein (RBP). All isolated mAbs neutralized HeV, and some also neutralized NiV. Epitope binning experiments identified five major antigenic sites on HeV-RBP. Animal studies demonstrated that the most potent cross-reactive neutralizing mAbs, HENV-26 and HENV-32, protected ferrets in lethal models of infection with NiV Bangladesh 3 days after exposure. We solved the crystal structures of mAb HENV-26 in complex with both HeV-RBP and NiV-RBP and of mAb HENV-32 in complex with HeV-RBP. The studies reveal diverse sites of vulnerability on RBP recognized by potent human mAbs that inhibit virus by multiple mechanisms. These studies identify promising prophylactic antibodies and define protective epitopes that can be used in rational vaccine design.
PubMed: 33306954
DOI: 10.1016/j.cell.2020.11.023
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.4 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon